Status:
COMPLETED
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborating Sponsors:
Sanofi
Conditions:
Pulmonary Tuberculosis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Protocol Synopsis The goal of this Phase 2 clinical trial is to evaluate the antimicrobial activity and safety of an experimental intensive phase (first 8 weeks of treatment) tuberculosis treatment re...
Eligibility Criteria
Inclusion
- Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated or induced sputum.
- Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 3 months prior to enrollment.
- 5 (five) or fewer days of multidrug therapy for tuberculosis disease in the 6 months preceding initiation of study drugs.
- 7 (seven) or fewer days of fluoroquinolone therapy in the 30 days preceding initiation of study drugs.
- Age \>= 18 years
- Karnofsky score of at least 60 (requires occasional assistance but is able to care for most of his/her needs; see Appendix B)
- Signed informed consent
- Women of child-bearing potential must agree to practice an adequate (barrier) method of birth control or to abstain from heterosexual intercourse during study therapy.
- Laboratory parameters done within 14 days prior to, enrollment:
- Serum or plasma alanine aminotransferase (ALT) activity ≤ 3 times the upper limit of normal
- Serum or plasma total bilirubin level ≤ 2.5 times the upper limit of normal
- Serum or plasma creatinine level ≤ 2 times the upper limit of normal
- Complete blood count with hemoglobin level of at least 7.0 g/dL
- Complete blood count with platelet count of at least 100,000/mm3
- Negative pregnancy test (women of childbearing potential)
Exclusion
- Pregnant or breast-feeding
- Known intolerance or allergy to any of the study drugs
- Concomitant disorders or conditions for which isoniazid (INH), rifamycins, pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These include severe hepatic damage, acute liver disease of any cause, and acute uncontrolled gouty arthritis.
- Current or planned therapy, during the intensive phase of TB therapy, with combination antiretroviral therapy for HIV, or with cyclosporine or tacrolimus. Cyclosporine and tacrolimus have unacceptable interactions with rifamycins.
- Pulmonary silicosis
- Central nervous system TB
- Weight \< 40 kg or \> 85 kg
Key Trial Info
Start Date :
December 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
865 Patients enrolled
Trial Details
Trial ID
NCT00694629
Start Date
December 1 2008
End Date
December 1 2013
Last Update
May 8 2014
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Arkansas Veterans Health System
Little Rock, Arkansas, United States, 72205
2
LA County/USC Medical Center
Los Angeles, California, United States, 90033
3
University of Southern California Medical Center
Los Angeles, California, United States, 90033
4
University of California at San Diego
San Diego, California, United States, 92103